File downloaded on 2025-12-27

Source URL: https://medicines.health.europa.eu/veterinary/en/600000985590

Pyrocam 15 mg/ml oral suspension for pigs

Authorised

Meloxicam

Product identification

Medicine name:

Pyrocam 15 mg/ml oral suspension for pigs

Pyrocam 15 mg/ml πόσιμο εναιώρημα για χοίρους

Active substance:

Meloxicam

Target species:

Pig

Route of administration:

Oral use

Product details

Active substance and strength:

Meloxicam

15.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Oral suspension

Withdrawal period by route of administration: Oral use:

•

Pig

- Meat and offal. 5 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

OM01AC06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Greece

Package description:

Cardboard box with HDPE bottle of 1000 ml closed with a two-part tamper evident closure consisting of an outer white cap (PP), an internal natural colour screw closure (HDPE) and a mounted plug (LDPE) + plastic measuring syringe Cardboard box with HDPE bottle of 250 ml closed with a two-part tamper evident closure consisting of an outer white cap (PP), an internal natural colour screw closure (HDPE) and a mounted plug (LDPE) + plastic measuring syringe Cardboard box with HDPE bottle of 125 ml closed with a two-part tamper evident closure consisting of an outer white cap (PP), an internal natural colour screw closure (HDPE) and a mounted plug (LDPE) + plastic measuring syringe

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application – bioavailability studies cannot be used to demonstrate bioequivalence (Article 19(1)(b) of Regulation (EU) 2019/6)

Marketing authorisation holder:

HuVepharma

Marketing authorisation date:

14/02/2024

Manufacturing sites for batch release:

Biovet AD

Responsible authority:

National Organization For Medicines

Authorisation number:

18915/15-02-2024/K-0255101

Date of authorisation status change:

14/02/2024

Reference member state:

Belgium

Procedure number:

BE/V/0048/001

Concerned member states:

Austria Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.